🔬 How CDSCO Monitors Drug Quality in India: Understanding NSQ Alerts, Factory Inspections & What International Buyers Should Know
India is one of the world’s largest producers of generic medicines, supplying over 20% of the global demand by volume. With this scale comes the critical responsibility of ensuring drug quality and safety. The Central Drugs Standard Control Organisation (CDSCO), India’s national drug regulatory authority, operates a comprehensive quality monitoring system that protects both domestic patients and international buyers.
In this guide, we explain how CDSCO monitors drug quality through NSQ (Not of Standard Quality) alerts, factory inspections, laboratory testing, and the new 2026 risk-based classification system — and what these processes mean for you as an international buyer of Indian generics.
📋 What Is CDSCO and What Does It Regulate?
The CDSCO is the national regulatory authority for pharmaceuticals and medical devices in India, operating under the Ministry of Health and Family Welfare. Its primary responsibilities include:
- Approval of new drugs and clinical trials
- Setting standards for drug manufacturing, import, and sale
- Monitoring quality of drugs already in the market
- Licensing of drug manufacturing and import establishments
- Coordinating with state drug control authorities for enforcement
The Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945 form the legal backbone of CDSCO’s authority. In 2025–2026, the regulator has undergone significant modernization to strengthen its oversight capabilities (as reported by The Pharma Letter, February 2026).
🛡️ The NSQ (Not of Standard Quality) Alert System
One of CDSCO’s most transparent quality control mechanisms is the monthly NSQ alert system. Every month, the regulator publishes a list of drug samples that have failed quality testing.
Recent NSQ Data (2025–2026)
- January 2026: 147 medicine samples flagged as NSQ, as reported by Medical Dialogues (February 2026)
- March 2026: 168 drug samples declared NSQ — 48 from central laboratories and 120 from state-level testing, as reported by ETV Bharat and ETPharma.com (April 2026)
- April 2026: 169 drug samples failed quality tests, including one batch of Ursodeoxycholic Acid (a liver drug) flagged as spurious, as reported by Business Standard and Free Press Journal (May 2026)
- June 2025: 55 drug batches flagged as NSQ and 4 as spurious, as reported by Medical Dialogues
What this means: These numbers represent a fraction of the total drug samples tested each month. The vast majority of Indian generic medicines meet quality standards. The NSQ system demonstrates CDSCO’s commitment to transparency — it publicly names failing manufacturers and removes substandard products from the supply chain.
🏭 India’s 2026 3-Tier Risk-Based Manufacturing Classification
In March 2026, the Indian government introduced a landmark 3-tier risk-based classification system for drug manufacturing facilities, as detailed by India Briefing (March 2026). This system categorizes manufacturers based on their compliance history and risk profile:
- Tier 1 — Low Risk: Manufacturers with consistent GMP compliance and no adverse quality findings. These facilities face reduced inspection frequency.
- Tier 2 — Medium Risk: Manufacturers with minor compliance gaps. These receive standard periodic inspections.
- Tier 3 — High Risk: Manufacturers with significant quality violations or repeated NSQ findings. These face increased scrutiny, more frequent inspections, and potential license suspension.
This classification is a significant step toward aligning India’s regulatory framework with global best practices, similar to the USFDA’s risk-based inspection scheduling model. It means that international buyers can increasingly rely on a manufacturer’s tier status as a quick proxy for quality reliability.
🔎 CDSCO’s Factory Inspection and GMP Audit Process
CDSCO, in coordination with State Drug Control Authorities, conducts routine and for-cause inspections of drug manufacturing facilities across India. Key aspects include:
- Pre-licensing inspection: Before a manufacturing license is issued, facilities must demonstrate compliance with Schedule M (India’s GMP standard)
- Periodic surveillance: Licensed facilities undergo regular inspections to ensure ongoing compliance
- For-cause inspections: Triggered by complaints, NSQ findings, or adverse event reports
- Post-approval change inspections: In March 2026, CDSCO introduced draft legislation requiring manufacturers to inform the regulator about manufacturing changes (as reported by RAPS.org, March 2026)
India’s Schedule M was revised in 2024 to align more closely with WHO-GMP standards, requiring manufacturers to implement quality management systems, validated processes, and comprehensive documentation — bringing Indian generics closer to international quality benchmarks.
🌍 What International Buyers Should Look For
As an international buyer of Indian generic medicines, CDSCO’s quality monitoring system is your ally — not an obstacle. Here is what you should check when evaluating a supplier:
- ✓ WHO-GMP Certificate: Verify that the manufacturer holds a valid WHO-GMP certificate issued by CDSCO or a recognized authority
- ✓ No NSQ History: Search the manufacturer’s name against CDSCO’s monthly NSQ lists (published on the CDSCO website)
- ✓ USFDA/EU-GMP Approvals: Many top Indian manufacturers also hold USFDA or EMA approvals — a strong indicator of dual compliance
- ✓ CDSCO Manufacturing License: Ensure the supplier’s license number is valid by cross-referencing with state drug authority records
- ✓ Batch Test Reports: Request Certificate of Analysis (CoA) for specific batches you intend to purchase
For a list of verified and reliable pharmaceutical distributors who source only from CDSCO-compliant manufacturers, refer to the IMSDA’s verified member directory.
⚠️ Distinguishing “NSQ” from “Spurious” and “Adulterated”
It is important to understand the different classifications CDSCO uses when flagging drugs:
- Not of Standard Quality (NSQ): The drug fails one or more quality parameters (e.g., dissolution, potency, impurities) but is not deliberately fraudulent. This is the most common finding.
- Spurious: A deliberately counterfeit or misbranded product. These are the most dangerous and subject to criminal prosecution. In April 2026, CDSCO flagged one batch as spurious (Ursodeoxycholic Acid, per Business Standard).
- Adulterated / Misbranded: Contains undeclared ingredients or false labeling.
The distinction matters: NSQ findings indicate a quality control failure at the manufacturing level (often correctable), while spurious findings indicate criminal counterfeiting.
🔮 The Future: CDSCO’s Path to Global Credibility
In 2026, CDSCO is implementing several reforms aimed at elevating its standing as a Stringent Regulatory Authority (SRA) — a status that would allow Indian drug approvals to be recognized by major global regulators like the USFDA and EMA:
- Risk-based oversight model: Prioritizing inspection resources toward high-risk facilities, as reported by The Pharma Letter (February 2026)
- Prior intimation system for clinical trials: Accelerating study startup timelines, as reported by RAPS.org (April 2026)
- Online portals for licensing and registration: Digitizing regulatory workflows for faster processing
- Building a 1,500-expert scientific cadre: Expanding the regulator’s technical workforce to improve review and inspection capacity
These reforms signal a clear trajectory: Indian generic medicines are becoming safer, better regulated, and more trusted on the global stage.
✅ Quick Checklist for International Buyers
Use this checklist when evaluating an Indian generic medicine supplier:
- [ ] Verify WHO-GMP certification (check CDSCO portal or ask manufacturer directly)
- [ ] Check manufacturer name against recent NSQ alerts (cdsco.gov.in → Monthly Drug Alerts)
- [ ] Confirm valid CDSCO manufacturing license number
- [ ] Request batch-specific Certificate of Analysis (CoA)
- [ ] Verify distributor through IMSDA’s verified member directory
- [ ] Check for USFDA or EU-GMP approval as additional quality signal
- [ ] Review product packaging for batch number, manufacturing date, and expiry date
For more information about sourcing quality Indian generic medicines, contact IMSDA at contact@indiamedicine.org.